![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Apollon Formularies plc | AQSE:APOL | Aquis Stock Exchange | Ordinary Share | IM00BJ0LRD77 | Ordinary shares |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAPOL 11 April 2023 Apollon Formularies Plc Result of GM Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK-based international medical cannabis pharmaceutical company specialising in cutting edge research and treatment of patients with various conditions including cancer, chronic pain and epilepsy, is pleased to announce that following the Company's General Meeting held on 11 April 2023, all resolutions were duly passed. As announced on 21 March 2023, the 28-day due diligence period extended to Global Hemp Group is expected to conclude on 28 April 2023. A further announcement will be made in due course. The Asset disposal circular remains available at https://apollon.org.uk/. The Directors of the Company accept responsibility for the contents of this announcement. -ENDS- For additional information, please visit www.apollon.org.uk or contact: Apollon Formularies Tel: +44 771 198 0221 Stene Jacobs stene@apollon.org.uk Peterhouse Capital Limited (Corporate Adviser) Tel: +44 207 220 9795 Guy Miller gm@peterhousecapital.com BlytheRay (Financial PR/IR-London) Tel: +44 207 138 3204 Tim Blythe/Megan Ray apollon@blytheray.com About Apollon Formularies and Apollon Formularies Jamaica Apollon Formularies plc is an international medical cannabis and medicinal mushroom pharmaceutical company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate, perform research and development, process, and sell therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision. Apollon's proprietary medical cannabis formulations have undergone third-party testing which demonstrated the successful killing of nearly 100% of prostate, triple negative and HER2+ breast cancer cells in 3D cell cultures. Apollon's products are also used to treat patients suffering from different conditions, including chronic pain and epilepsy. END
(END) Dow Jones Newswires
April 11, 2023 09:00 ET (13:00 GMT)
1 Year Apollon Formularies Chart |
1 Month Apollon Formularies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions